Air Liquide has increased production and inventory of essential medical gases, like oxygen, and is actively managing its gas assets and safety hardgoods inventory to prioritize the needs of the U.S. healthcare system and government.
HOUSTON–(BUSINESS WIRE)–Air Liquide, a world leader in gases, technologies and services for industry and health, stands ready to support the critical efforts of the healthcare industry and U.S. government in combating the COVID-19 pandemic in the U.S. With a presence in over 80 countries globally, Air Liquide is fully mobilized to respond to the increasing need for medical oxygen and continue to service other essential businesses to bring stability to the supply chain.
Since the beginning of the coronavirus outbreak, Air Liquide in the U.S. has activated business continuity plans to maximize efficiency and maintain its activities, while increasing its medical gas production capabilities to meet the current demand. Air Liquide has been proactively communicating with medical customers, specifically hospitals, through its region-based specialists to appropriately manage the supply of the most critically needed medical gases, such as oxygen.
In addition to maintaining the highest inventory levels at customers’ onsite liquid medical oxygen storage units and within the fill plants of Airgas, an Air Liquide company, Air Liquide is also working to shift excess cylinder assets to areas with the greatest anticipated need and is preparing portable assets to serve the eventual oxygen needs of mobile treatment centers. Air Liquide continues to serve as a vital partner to communities and is working in partnership with local government officials to ensure an uninterrupted source of assets during this critical time. As healthcare demands increase, Air Liquide reinforces its focus on safely fulfilling the industrial gas needs of its customers in key support industries, including refining, energy, food service and pharmaceuticals.
Michael Graff, Chairman & CEO, American Air Liquide Holdings, Inc. and Air Liquide Group Executive Vice President, said: “Air Liquide is honored to play a vital role in serving our healthcare system and its essential workers during this unprecedented health crisis through the reliable and safe delivery of critically important medical gases, like oxygen, and safety materials. As we navigate through these unprecedented times, Air Liquide remains committed to serve the critical needs of customers in healthcare, food, pharmaceuticals, energy and refining with excellence, so that these vital industries and services continue to operate for the good of our communities and for the resilient and sustainable growth of our economy.”
A world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with approximately 67,000 employees and serves more than 3.7 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide’s scientific territory and have been at the core of the company’s activities since its creation in 1902.
Air Liquide’s ambition is to be a leader in its industry, deliver long term performance and contribute to sustainability. The company’s customer-centric transformation strategy aims at profitable, regular and responsible growth over the long term. It relies on operational excellence, selective investments, open innovation and a network organization implemented by the Group worldwide. Through the commitment and inventiveness of its people, Air Liquide leverages energy and environment transition, changes in healthcare and digitization, and delivers greater value to all its stakeholders.
Air Liquide’s revenue amounted to 22 billion euros in 2019 and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indexes.
+33 (0)1 40 62 58 49
Air Liquide Americas Communications
+1 713 548-6056
Paris – France
+33 (0)1 40 62 50 87
Philadelphia – USA
+1 610 263 8277